List of Tables
Table 1. Global Duvelisib for Relapsed CLL/SLL Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Duvelisib for Relapsed CLL/SLL Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Duvelisib for Relapsed CLL/SLL Market Competitive Situation by Manufacturers in 2025
Table 4. Global Duvelisib for Relapsed CLL/SLL Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Duvelisib for Relapsed CLL/SLL Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Duvelisib for Relapsed CLL/SLL Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Duvelisib for Relapsed CLL/SLL Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Duvelisib for Relapsed CLL/SLL, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Product Types and Applications
Table 12. Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Duvelisib for Relapsed CLL/SLL Companies by Tier (Tier 1, Tier 2, Tier 3), based on Duvelisib for Relapsed CLL/SLL Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Duvelisib for Relapsed CLL/SLL Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Duvelisib for Relapsed CLL/SLL Sales by Region (K Units), 2021–2026
Table 18. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Region (2021–2026)
Table 19. Global Duvelisib for Relapsed CLL/SLL Sales by Region (K Units), 2027–2032
Table 20. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Region (2027–2032)
Table 21. Global Duvelisib for Relapsed CLL/SLL Revenue by Region (US$ Million), 2021–2026
Table 22. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Region (2021–2026)
Table 23. Global Duvelisib for Relapsed CLL/SLL Revenue by Region (US$ Million), 2027–2032
Table 24. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Region (2027–2032)
Table 25. North America Duvelisib for Relapsed CLL/SLL Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2021–2026
Table 27. North America Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2027–2032
Table 28. North America Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2021–2026
Table 29. North America Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Duvelisib for Relapsed CLL/SLL Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2021–2026
Table 32. Europe Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2027–2032
Table 33. Europe Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Duvelisib for Relapsed CLL/SLL Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Duvelisib for Relapsed CLL/SLL Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Duvelisib for Relapsed CLL/SLL Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Duvelisib for Relapsed CLL/SLL Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Duvelisib for Relapsed CLL/SLL Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Duvelisib for Relapsed CLL/SLL Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2021–2026
Table 42. Latin America Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2027–2032
Table 43. Latin America Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Duvelisib for Relapsed CLL/SLL Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2027–2032
Table 50. Global Duvelisib for Relapsed CLL/SLL Sales (K Units) by Type (2021–2026)
Table 51. Global Duvelisib for Relapsed CLL/SLL Sales (K Units) by Type (2027–2032)
Table 52. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Type (2021–2026)
Table 53. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Type (2027–2032)
Table 54. Global Duvelisib for Relapsed CLL/SLL Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Duvelisib for Relapsed CLL/SLL Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Type (2021–2026)
Table 57. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Type (2027–2032)
Table 58. Global Duvelisib for Relapsed CLL/SLL Price (US$/Unit) by Type (2021–2026)
Table 59. Global Duvelisib for Relapsed CLL/SLL Price (US$/Unit) by Type (2027–2032)
Table 60. Global Duvelisib for Relapsed CLL/SLL Sales (K Units) by Application (2021–2026)
Table 61. Global Duvelisib for Relapsed CLL/SLL Sales (K Units) by Application (2027–2032)
Table 62. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Application (2021–2026)
Table 63. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Application (2027–2032)
Table 64. Global Duvelisib for Relapsed CLL/SLL Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Duvelisib for Relapsed CLL/SLL Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Application (2021–2026)
Table 67. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Application (2027–2032)
Table 68. Global Duvelisib for Relapsed CLL/SLL Price (US$/Unit) by Application (2021–2026)
Table 69. Global Duvelisib for Relapsed CLL/SLL Price (US$/Unit) by Application (2027–2032)
Table 70. Secura Bio Company Information
Table 71. Secura Bio Description and Business Overview
Table 72. Secura Bio Duvelisib for Relapsed CLL/SLL Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Secura Bio Duvelisib for Relapsed CLL/SLL Product
Table 74. Secura Bio Recent Developments/Updates
Table 75. CSPC Company Information
Table 76. CSPC Description and Business Overview
Table 77. CSPC Duvelisib for Relapsed CLL/SLL Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. CSPC Duvelisib for Relapsed CLL/SLL Product
Table 79. CSPC Recent Developments/Updates
Table 80. Key Raw Materials Lists
Table 81. Raw Materials Key Suppliers Lists
Table 82. Duvelisib for Relapsed CLL/SLL Distributors List
Table 83. Duvelisib for Relapsed CLL/SLL Customers List
Table 84. Duvelisib for Relapsed CLL/SLL Market Trends
Table 85. Duvelisib for Relapsed CLL/SLL Market Drivers
Table 86. Duvelisib for Relapsed CLL/SLL Market Challenges
Table 87. Duvelisib for Relapsed CLL/SLL Market Restraints
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
Table 91. Authors List of This Report
List of Figures
Figure 1. Product Picture of Duvelisib for Relapsed CLL/SLL
Figure 2. Global Duvelisib for Relapsed CLL/SLL Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Duvelisib for Relapsed CLL/SLL Market Share by Type: 2025 & 2032
Figure 4. 25mg Product Picture
Figure 5. 15mg Product Picture
Figure 6. Global Duvelisib for Relapsed CLL/SLL Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Duvelisib for Relapsed CLL/SLL Market Share by Application: 2025 & 2032
Figure 8. Chronic Lymphocytic Leukemia (CLL)
Figure 9. Small Lymphocytic Lymphoma (SLL)
Figure 10. Global Duvelisib for Relapsed CLL/SLL Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 11. Global Duvelisib for Relapsed CLL/SLL Market Size (US$ Million), 2021–2032
Figure 12. Global Duvelisib for Relapsed CLL/SLL Sales (K Units), 2021–2032
Figure 13. Global Duvelisib for Relapsed CLL/SLL Average Price (US$/Unit), 2021–2032
Figure 14. Duvelisib for Relapsed CLL/SLL Report Years Considered
Figure 15. Duvelisib for Relapsed CLL/SLL Sales Share by Manufacturers in 2025
Figure 16. Global Duvelisib for Relapsed CLL/SLL Revenue Share by Manufacturers in 2025
Figure 17. Top 5 and Top 10 Global Duvelisib for Relapsed CLL/SLL Players: Market Share by Revenue in Duvelisib for Relapsed CLL/SLL in 2025
Figure 18. Duvelisib for Relapsed CLL/SLL Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 19. Global Duvelisib for Relapsed CLL/SLL Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 20. North America Duvelisib for Relapsed CLL/SLL Sales Market Share by Country (2021–2032)
Figure 21. North America Duvelisib for Relapsed CLL/SLL Revenue Market Share by Country (2021–2032)
Figure 22. United States Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 23. Canada Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Europe Duvelisib for Relapsed CLL/SLL Sales Market Share by Country (2021–2032)
Figure 25. Europe Duvelisib for Relapsed CLL/SLL Revenue Market Share by Country (2021–2032)
Figure 26. Germany Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. France Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. U.K. Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Italy Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Russia Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Asia Pacific Duvelisib for Relapsed CLL/SLL Sales Market Share by Region (2021–2032)
Figure 32. Asia Pacific Duvelisib for Relapsed CLL/SLL Revenue Market Share by Region (2021–2032)
Figure 33. China Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Japan Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. South Korea Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. India Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Australia Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. China Taiwan Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Southeast Asia Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Latin America Duvelisib for Relapsed CLL/SLL Sales Market Share by Country (2021–2032)
Figure 41. Latin America Duvelisib for Relapsed CLL/SLL Revenue Market Share by Country (2021–2032)
Figure 42. Mexico Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Brazil Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Argentina Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Colombia Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Middle East and Africa Duvelisib for Relapsed CLL/SLL Sales Market Share by Country (2021–2032)
Figure 47. Middle East and Africa Duvelisib for Relapsed CLL/SLL Revenue Market Share by Country (2021–2032)
Figure 48. Turkey Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Saudi Arabia Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. UAE Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Global Sales Market Share of Duvelisib for Relapsed CLL/SLL by Type (2021–2032)
Figure 52. Global Revenue Market Share of Duvelisib for Relapsed CLL/SLL by Type (2021–2032)
Figure 53. Global Duvelisib for Relapsed CLL/SLL Price (US$/Unit) by Type (2021–2032)
Figure 54. Global Sales Market Share of Duvelisib for Relapsed CLL/SLL by Application (2021–2032)
Figure 55. Global Revenue Market Share of Duvelisib for Relapsed CLL/SLL by Application (2021–2032)
Figure 56. Global Duvelisib for Relapsed CLL/SLL Price (US$/Unit) by Application (2021–2032)
Figure 57. Duvelisib for Relapsed CLL/SLL Value Chain
Figure 58. Channels of Distribution (Direct Vs Distribution)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed